Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) Shares Outstanding (Weighted Average) (2023 - 2025)

Immunome's Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $87.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 48.96% year-over-year to $87.4 million; the TTM value through Dec 2025 reached $87.4 million, up 48.96%, while the annual FY2025 figure was $87.4 million, 48.96% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $87.4 million in Q4 2025 per IMNM's latest filing, down from $88.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $88.0 million in Q3 2025 to a low of $157314.0 in Q1 2024.
  • Average Shares Outstanding (Weighted Average) over 3 years is $45.8 million, with a median of $57.2 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): plummeted 98.71% in 2024, then skyrocketed 50378.89% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $500000.0 in 2023, then surged by 11627.89% to $58.6 million in 2024, then surged by 48.96% to $87.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's Shares Outstanding (Weighted Average) are $87.4 million (Q4 2025), $88.0 million (Q3 2025), and $83.2 million (Q2 2025).